- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00002150
A Study of the Safety and Efficacy of Chronically Administered MDL 28,574A in the Treatment of HIV-Infected Patients
June 23, 2005 updated by: Hoechst Marion Roussel
To characterize the safety and efficacy of fixed doses of MDL 28,574A administered alone and in combination with zidovudine ( AZT ) in patients with asymptomatic or mildly symptomatic HIV infection.
To examine the demographic effects on population pharmacokinetics and pharmacodynamics of MDL 28,574A alone and in combination with AZT.
Study Overview
Study Type
Interventional
Enrollment
200
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Mobile, Alabama, United States, 366880002
- Clinical Investigations Health Services
-
-
California
-
Beverly Hills, California, United States, 90211
- California Clinical Trials Med Group
-
Los Angeles, California, United States, 90027
- Southwest Community Based AIDS Treatment Group - COMBAT
-
San Francisco, California, United States, 94110
- UCSF - San Francisco Gen Hosp
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20037
- George Washington Univ / Hershey Med Ctr
-
-
Florida
-
Coral Gables, Florida, United States, 33146
- Community Research Initiative of South Florida
-
Fort Lauderdale, Florida, United States, 33316
- North Broward Hosp District
-
Fort Lauderdale, Florida, United States, 33316
- Independent Investigator
-
Sarasota, Florida, United States, 34239
- Clinical Research Ctr
-
Vero Beach, Florida, United States, 32960
- Independent Investigator
-
-
Illinois
-
Chicago, Illinois, United States, 60657
- Ctr for Special Immunology
-
-
Indiana
-
Indianapolis, Indiana, United States, 462025250
- Indiana Univ Hosp
-
-
Kansas
-
Wichita, Kansas, United States, 67214
- Univ of Kansas School of Medicine
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Univ Health Ctr
-
-
Missouri
-
Kansas City, Missouri, United States, 64132
- Antibiotic Research Associates
-
-
New Jersey
-
Newark, New Jersey, United States, 071032842
- North Jersey Community Research Initiative
-
-
New York
-
Rochester, New York, United States, 14620
- Community Health Network
-
Stony Brook, New York, United States, 117948153
- SUNY / Health Sciences Ctr at Stony Brook
-
-
Ohio
-
Toledo, Ohio, United States, 43608
- Infectious Disease Associates
-
-
Pennsylvania
-
Sayre, Pennsylvania, United States, 18840
- Guthrie Clinic
-
-
Texas
-
Dallas, Texas, United States, 752359103
- Univ of Texas Southwestern Med Ctr of Dallas
-
Galveston, Texas, United States, 775550835
- Univ TX Galveston Med Branch
-
Houston, Texas, United States, 77006
- Houston Clinical Research Network
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria
Patients must have:
- HIV infection.
- Asymptomatic or mildly symptomatic.
- CD4 count 100 - 300 cells/mm3.
Prior Medication:
Allowed:
- Prior antiretroviral agents for up to 6 months per agent.
Exclusion Criteria
Co-existing Condition:
Patients with the following condition are excluded:
Unable or unwilling to comply with study procedures.
Concurrent Medication:
Excluded:
- Chemoprophylactic therapy for mycobacterial infection.
- Any nonstudy prescription medications without approval of investigator.
Patients with the following prior conditions are excluded:
- History of grade 3 or 4 toxicity to <= 600 mg/day AZT.
- History of intolerance to lactose.
- Chronic diarrhea within 6 months prior to study entry.
- Unexplained intermittent or chronic fever, defined as temperature >= 38.5 C for any 7 days within the 30 days prior to study entry.
Prior Medication:
Excluded:
- Antiretroviral therapy within 2 weeks prior to study entry.
- Prior HIV vaccines.
- Biological response modifiers within 30 days prior to study entry.
- Prior foscarnet.
- Any investigational drug with a washout < 5 half-lives prior to study entry.
- Any medications known to alter renal, hepatic, or hematologic / immunologic function (such as barbiturates, phenothiazines, cimetidine, immunomodulators, etc.) within 14 days prior to study entry.
Recent history of alcohol and/or drug abuse.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Masking: DOUBLE
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
November 2, 1999
First Submitted That Met QC Criteria
August 30, 2001
First Posted (ESTIMATE)
August 31, 2001
Study Record Updates
Last Update Posted (ESTIMATE)
June 24, 2005
Last Update Submitted That Met QC Criteria
June 23, 2005
Last Verified
March 1, 1996
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 221B
- 028574PR0003
- NDPR0003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infections
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
University of California, San DiegoUniversity of California, Los Angeles; University of Southern California; California... and other collaboratorsCompleted
-
Gérond'ifRecruiting
-
University of California, DavisCompleted
-
University of California, San DiegoNational Center for Complementary and Integrative Health (NCCIH)CompletedHIV PositiveUnited States
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completed
-
HIV Prevention Trials NetworkNational Institute on Drug Abuse (NIDA); National Institute of Allergy and...CompletedHIV PositiveIndonesia, Ukraine, Vietnam
-
University of ZimbabweCompleted
-
Florida International UniversityCompleted
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completed
Clinical Trials on Celgosivir hydrochloride
-
Hoechst Marion RousselCompleted
-
Hoechst Marion RousselCompleted
-
BioWest Therapeutics IncCompleted
-
Singapore General HospitalDuke-NUS Graduate Medical School; 60 Degrees Pharmaceuticals LLCWithdrawn
-
Singapore General HospitalDuke-NUS Graduate Medical SchoolCompleted
-
BioWest Therapeutics IncCompleted
-
BioWest Therapeutics IncCompleted
-
BioWest Therapeutics IncUnknown
-
Xijing Hospital of Digestive DiseasesCompleted
-
Xijing Hospital of Digestive DiseasesCompletedColorectal AdenomasChina